Dermatology
Partner With Us
Advertisement
Conexiant chevron_right Dermatology chevron_right FDA & Government News

FDA & Government News

thumb description

June 30, 2026

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

Conexiant

thumb description

June 29, 2026

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

Conexiant

thumb description

June 29, 2026

Where Are Adults Getting Sunburned?

Water-related activities were the most commonly reported setting for recent sunburn, while more than one-half of respondents reported sunscreen use at the time of their most recent sunburn.

Conexiant

thumb description

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

thumb description

June 09, 2026

FDA Permits New Sunscreen Ingredient After 20 Years

The sunscreen ingredient, which has been marketed internationally for years, is considered generally recognized as safe and effective for use in adults and pediatric patients aged 6 months and older.

Conexiant

thumb description

May 18, 2026

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Conexiant